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DNA-carcinogen adducts offerapotential dosimeter forenvironmental genotoxicants reachingtheexposed
individual. Becausethetargettissuesformanychemical carcinogens arenotreadilyaccessibleformonitoring
adducts in humans, peripheral blood lymphocytes (PBLs) have served as surrogate sources ofexposed DNA.
Both benzo[a]pyrene (BaP) and benzo[b]fluoranthene (BbF) are widely distributed in the environment as
components ofcomplex mixtures, such as automobile exhaust, cigarette smoke, foods, water, and urban air.
Thus, human exposure to these chemicals is widespread, and they probably contribute to overall human lung
cancer risk. The interpretation ofthe results of such studies would be enhanced by an understanding ofthe
pharmacokinetics of specific DNA adduct formation and persistence in both target and surrogate tissues.
Polycyclic aromatic hydrocarbons (PAHs) were administered to male Sprague-Dawley rats IP at 100 mgPAH/
kgbodyweight. Lung,liver,andPBLtissues wereharvested1,3,7,14,28,and56days aftertreatment. DNAwas
extracted from each tissue and32P-postlabeling analysis ofDNA adducts with nuclease P1 enhancement was
conducted. In all three tissues, BaP-DNA adducts exhibit a similar pattern, reaching a maximum at 34 days,
followedbyadecrease to 56 days. For BbF, the maximum DNA adduct levels in eachtissue werebetween 5 and
14 days after injection. By 56 days after administration, the total adducts remaining in all tissues were
measurable.Correlation analysesoftheamountofDNAadductsinlungorlivercomparedtothosefoundinthe
PBL ofthe same animals suggest arange ofcorrelations (R2 = 0.67-0.83). ForBaP, DNAadducts inbothliver
and lung may be predicted by PBL DNA adduct levels. For BbF, adduct levels in PBLs directly reflect adduct
levels inthe liverand arelesspredictive oflungadductlevels.Thecollateral pharmacokinetics forDNAadduct
persistence in lung, liver, and PBLs suggest that PBL adduct-based dosimetry may reflect patterns of
adduction in other less accessible tissues. Thus, PBL DNA adducts may prove to be useful dosimeters for the
delivered dose ofDNA.
Introduction
DNA-carcinogen adducts mayoffer apotential dosime-
ter for environmental genotoxicants reaching the exposed
individual. Since the advent of sensitive techniques that
can measure DNA adducts in human tissues at extremely
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high levels ofsensitivity, there has been numerous papers
describing studies on DNAadducts in humans exposed to
environmental agents. Industrial populations exposed to
processes such as aluminum smelters (1), coke ovens (2),
iron and steel foundries (3), and roofing (4), and popula-
tions exposed to cigarette smoke (5) and genotoxic agents
have been studied (6). In all of these studies, peripheral
blood lymphocytes (PBLs) have be used as the accessible
target tissue in which to measure the formation of DNA
adducts. Because the target tissues for many chemical
carcinogens are not readily accessible for monitoring
adducts in humans, PBLs have served as surrogate
sources ofexposed DNA. Theinterpretation oftheresults
ofsuch studieswould be enhancedby anunderstanding of
the pharmacokinetics of specific DNA adduct formation
and persistence in both target and surrogate tissues.NESNOW ET AL.
Benzo[a]pyrene (BaP) and benzo[b]fluoranthene (BbF)
are bay-region-containing polycyclic aromatic hydrocar-
bons (PAHs) widely distributed in the environment as
components of complex mixtures, found in automobile
exhaust, cigarette smoke, foods, water, and urban air (7).
PAHs are components ofmanyemissions arisingfromthe
combustion of coal, petroleum fuels, and plant materials
(7). The goals of this study were to examine time-course
relationships between BaP and BbF administration and
DNA adduct formation and persistence in accessible and
target rat tissues and to identify novel DNA adducts
formed in target tissues to relate to their mechanisms of
metabolic activation in chemical carcinogenesis. This
paper reviews previous work in this study, presents new
data, and outlines new research directions.
Materials and Methods
Male Sprague-Dawley rats 21 days old were obtained
from Charles River Breeding Laboratories (Morrisville,
NC)andwerehousedthreepercage. RatswerefedPurina
lab chow andwater ad libitum. Animals were maintained
at20-21°C,relativehumidity60-68%,ona12-hrlight-dark
cycle. At the time of PAH administration, the animals
weighedbetween 280gand 405 gandwere approximately
6 weeks old. PAHs were administered as a uniform sus-
pensioninsunflowerseedoilin asingle IPinjection at0.05
mL/10 g body weight to yield a final dose of 100 mg/kg.
Three animals were used for each time point, and control
animals received IP injections ofthe oil carrier alone.
Rats were anesthetized with Metofane, (methoxy-
flurane, Pitman-Moore, Washington Crossing, NJ) at
various times after PAH administration and approx-
imately 10 mL ofbloodwas removed bycardiac puncture.
The rats were then sacrificed by cervical dislocation, and
thelungs andliversweresurgicallyremovedandfrozen at
-800C. DNA was isolated from tissues by a spermine
precipitation method (8). Tissues from individual animals
were analyzed separately.
32P-Postlabeling Analysis ofDNA Adducts
DNA (5 ,ug/adduct assay) was hydrolyzed to 3'-
mononucleotides by digestion with micrococcal nuclease
and spleen phosphodiesterase aspreviously described (9).
The efficiency of adduct labeling relative to nonadducted
nucleotides was enhanced by digestion with nuclease P1,
as described by Reddy and Randerath (10). Adducts were
labeled at the 5' position with polynucleotide kinase and
`-32P-ATP. Radiolabeled adduct nucleotide bisphosphates
were then separated by thin-layer chromatography as
previously described (11). Two solvent systems were rou-
tinely employed. System 1 was Dl = 1 M sodium phos-
phate,pH6.0,withovernightchromatography onto a5-cm
Whatman grade 17 Chr wick, followed by a wash with
water; D3 = 3.5 Mlithiumformate, 7Murea,pH3.5,with
development 6-8 cm onto a Whatman-grade 1 wick, fol-
lowedbyawashwithwater, awashwith20 MmThisbase,
andanadditionalwashwithwater; D4 = 1:1 isopropanol:4
N ammonia, with development 6-8 cm onto a Whatman-
grade 1 wick; and D5 = 1.7 M sodium phosphate, pH 6.8,
with development 6 cm onto a Whatman-grade 1 wick.
System 2 was Dl = 1 M sodium phosphate, pH 6.0, with
overnight development onto a 10-cm Whatman-grade
3MM Chrwickfollowed byawashwithwater; D2 = 2.75
Mammoniumformate,developed 1 cm;D3 = 4.5Mlithium
formate, 7 Murea, pH 3.5, followedby awashwithwater;
D4 prewash = 1 cm developmentwith 0.5MTris-HCl; D4
= 1.1 Mlithiumchloride,0.5MTris-HCl, 7Murea,pH8.0,
followed by a wash with water; and D5 = 1.0 M MgCl2,
with development onto a 3-cmWhatman-grade 3MM Chr
wick, followed by a final wash with water. Separated
adductswerevisualizedbyautoradiographyusingDuPont
Cronex Lightning Plus intensifying screens and Kodak
XAR-5X-rayfilmovernightat -80 'C.Adductlevelswere
quantitated using the technique ofGupta (9).
Results
The single IP administration ofBaP to rats produced a
time-course relationship between BaP-DNA adduct for-
mation, persistence, and decay over a 56-dayperiod (Fig.
1). Thisrelationship shows anexpectedearlypeakofDNA
adduct formation and slow decline of adduct persistence
and decay. Maximal DNA adducts present in lung, liver,
and PBLs occur at approximately 3 days after a single IP
administration. Lung and liver DNA is adducted in the
pmole/mg DNA range, with PBL DNA adducted at one-
third that seen with lung DNA. The three tissues show
parallel DNA adduct formation, persistence, and decay
time-courserelationships overa56-dayperiod.At56days,
residual DNA adducts in each tissue are clearly measur-
able up to 150 fmole/mg DNA.
The DNA adduct autoradiograms from postlabeling
analysis revealed that each tissue produced unique pat-
tems of DNA adducts and that there were several novel
andasyetunidentified DNAadductsinbothlungandliver
DNA of these animals (12). Lung DNA contained the
expected benzo[a]pyrene diol-epoxide (BPDEI)-dGuo
DNA adduct with two slower migrating, major DNA
adducts. Liver DNAalso contained the expected BPDEI-
dGuoadductwithafastermigrating, newadduct(datanot
shown).
To identify these new adducts, a series ofBaP metabo-
lites and synthetic standards were administered to rats
and after 3 days lung, liver, and PBL DNA was isolated
and examined for the presence of specific BaP-DNA
adducts (12). The results of this analysis indicated that
although several BaP metabolites/standards produced
DNA adducts, only two produced DNA adducts that co-
migrated with DNA formed by administration of BaP
alone. 9-Hydroxy-BaP produced the new slower DNA
adducts seen in lungs from rats administered BaP, which
was confirmed byco-chromatography ofthe two DNAs in
several TLC solvent systems. trans-7,8-Dihydro-7,8-
dihydroxy-BaP produced the new adduct observed in the
liverofratsadministeredBaPaswellastheBPDEI-dGuo
DNA adduct.
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Administration ofBbF to rats at 100mg/kg by a single
IP administration produced a pattern of DNA adducts,
that, unlike BaP, was similar in all three tissues (13).
Quantitatively DNA adduct formation in the lung was
approximately five times that found in the liver or PBLs.
The peak of BbF-DNA adduct formation in all three
tissues occurred between 5 and 14 days after administra-
tion (Fig. 2). Loss ofDNAadducts in the lungwas slower
than that observed in the liver or PBLs with approx-
imately50% remainingafter56 days. Co-chromatography
ofDNAfromBbF-treatedratswithDNAreactedwiththe
bay-region diol-epoxide of BbF (trans-9,10-dihydro-9,10-
dihydroxy-BbF-11,12-oxide) indicated that almost none of
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the BbF-DNA adducts in the rat was related to the bay-
region diol-epoxide.
Discussion
BaP induces awide range oftumors in the rat depend-
ing on the route of administration. Systemic administra-
tion produces mammary tumors; esophageal and fore-
stomach tumors are produced by intragastric or oral
administration (14-17). Subcutaneous administration of
BaP produces both site of injection fibrosarcomas and
mammary tumors; intratracheal instillation and lung
implantationboth produced lungtumors (18-22). BbF has
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FIGURE 1. Accumulation, persistence, and decay ofbenzo[a]pyrene (BaP) DNA adducts in lung, liver, and peripheral blood lymphocytes from rats
administered a single IP dose of100 mg/kg BaP. Each point represents the mean ofduplicate determinations on tissues from each ofthree rats.
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FIGURE 2. Accumulation, persistence, and decay ofbenzo[b]fluoranthene (BbF)-DNA adducts in lung, liver, and peripheral blood lymphocytes from
rats administered a single IP dose of100mg/kg BbF. Each point represents the mean ofduplicate determinations on tissues from each ofthree rats.
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FIGURE 3. Correlation plots ofDNAadducts in lungorlivercompared to DNAadducts in peripheral blood lymphocytes based on all timepoints. (Left
panel) benzo[a]pyrene; (right panel) benzo[b]fluoranthene; (d) lung, (V) liver.
not been as widely studied in the rat. The only reported
study is a lung implantation study that produced lung
tumors (22). Thus, therespiratorytractismajortargetfor
both these PAHs in the rat.
The major question of the appropriateness of using
available surrogate tissues such as PBLs to monitorinter-
nal target tissue dose for several PAHs has been
answered. The BaP- and BbF-DNA adduct formation,
persistence, and decay curves over a 56-day period for
lung, liver, and PBL tissues areremarkably similar. Quan-
titative determination ofthis similaritycanbeobtainedby
examining the correlation coefficient between DNA
adducts in PBLs and DNAadducts inlung orlivertissues
over the complete time course study (Fig. 3). ForBaP, the
correlation coefficient between BaP-DNA adducts in
PBLs and BaP-DNA adducts in lung or liver range from
0.75 to 0.78, a very strong correlation (Table 1). For BbF,
the correlation coefficient between BbF-DNA adducts in
PBLs and BbF-DNAadducts in lungis 0.67, whereas the
correlation between DNA adducts in PBLs and liver is
0.83. This suggests that DNA adducts in PBLs can serve
as surrogates for DNA adducts in internal organs for
these PAHs with some confidence. The levels of DNA
adduction in the PBLs ofrats 56 days after treatment is
comparable to that found in PBLs obtained from humans
exposed to a variety of PAH-rich exposures including
Table 1. Correlation (R2) between PAH-DNA adduct levels in
PBLs and PAH-DNA adduct levels in lung and livertissues.a
PAH Lung Liver
BaP 0.78 0.75
BbF 0.67 0.83
Abbreviations: PAH, polycyclic aromatic hydrocarbon; PBL, peri-
pheral blood lymphocytes; BaP, benzo[a]pyrene; BbF, benzo[b]-
fluoranthene.
aCorrelations based on values at all time points from data found in
Figures 1 and 2. Correlation coefficients obtained from linear least
squares regression analysis.
those due to aluminum smelters, coke ovens, iron and steel
foundries, roofing tar emissions, cigarette smoking, and
psoriasis treatment with coal tar (Table 2). This places
more credence on these correlations, as they were not
totally based on comparisons at extremely high DNA
adduction levels.
The partial identification of the novel BaP-DNA
adducts that are further metabolites of trans-7,8-
dihydro-7,8-dihydroxy-BaP and 9-hydroxy-BaP has
prompted the synthesis of4,5-difluoro-BaP, a fluorinated
BaP blocked at the 4,5-bond or K-region (23). The litera-
turepriortothepostlabelingmethodologysuggested that
9-hydroxy-BaP may be further metabolized to a reactive
form (possibly 9-hydroxy-BaP-4,5-oxide) that can bind to
DNA, as indications of this adduct were observed in rat
liver and lung (24-25). Interestingly, rat liver microsomal
metabolism of 9-fluoro-BaP gives both trans-7,8-
dihydro-7,8-dihydroxy-9-fluoro-BaP and trans-4,5-
dihydro-4,5-dihydroxy-9-fluoro-BaP suggesting the 7,8
bond as a possible target for the second oxidation step of
9-hydroxy-BaP (39). Studies are underway to explore the
Table 2. Comparison oflevels ofPAH-DNA adducts
in rat and human PBLs.
Total DNA adducts
Species/exposure /108 nucleotides
Rat/BaP (after 56 days) 0.87
RatIBbF (after 56 days) 0.33
Human/Finnish foundry workers (3)a 0.75-2.5
Human/Polish coke oven workers (2) 15.3
Human/aluminum smelter workers (1) 1.48-3.08
Human/psoriasis patients treated with coal tar (6) 0.18-9.4
Human/cigarette smokers (5) 8-61
Human/roofers (4) 0.1-9.6
Abbreviations: PAH, polycyclic aromatic hydrocarbon; PBL, peri-
pheral blood lymphocytes; BaP, benzo[a]pyrene; BbF, benzo[b]fluor-
anthene.
aWhite blood cells.
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TAble 3. Summary ofapparent half-lives of
PAH-DNA adducts in three rat tissuesa
PAH Lung Liver PBLs
BaPb 22 (23)c 13 16
BbF 18 8 8
Abbreviations: PAH, polycyclic aromatic hydrocarbon; PBLs, peri-
pheral blood lymphocytes; BaP, benzo[a]pyrene; BbF, benzo[b]fluor-
anthene.
aDetermined from the exponential decay curves of a log-linear plot.
Values in days.
bBased on benzo[a]pyrene diol epoxide I-dGuo adduct.
cBased on 9-hydroxy-BaP-DNA adducts.
identity of the two new DNA adducts of BaP using this
fluorinated probe.
Our analysis ofthe pattern of DNA adducts from rats
treated with BbF suggests that none of the adducts are
related to the bay-region diol epoxide ofBbF (trans-9,10-
dihydro-9,10-dihydroxy-BbF-11,12-oxide). These results
are in concert with those found by analyzing DNA from
mouseepidermistreatedwithBbF (27).Although BbFis a
strong mouse skin tumor initiator, the major mouse skin
DNAadducts ofBbF are notrelated to thebay-region diol
epoxide.
Comparisonofthehalf-lives oftheDNAadductsineach
tissue for each PAH suggested that PAH-DNA adducts
persist longer in lungtissues than in liver or PBLs (Table
3). BaP-DNA adducts seem to persist twice as long as
BbF-DNAadducts for each tissue, with maximal half-life
times of 23 days recorded. The half-lives of these PAH-
DNAadducts in PBLs are 8-16 days. Experimental deter-
mination of the lifetimes of lymphocytes in humans and
mice have been studied. In women, there seems to be two
populations oflymphocytes, one short-lived (3-4days) and
another largerfraction that are long-lived [530 days (28)].
Similar results have been found in mice with a short-lived
fraction (3-5 days) and alargerlongerlivedfraction of112
days (29). In the rat, two populations oflymphocytes have
also been reported with lymphocyte lifetimes relatively
longer than those found in the mouse (30,31).
These studies in experimental animals are crucial to
developing the background for the use ofPBLs as surro-
gate tissues for biomonitoring exposure of humans to
genotoxic agents. They also provide a firm experimental
basis for the identification of the structure of the DNA
adductsbeingmonitoredandthetechniques forobserving
theseadductsinmorecomplexhumansamples.Theknowl-
edgeofthecollateralpharmacokinetics ofDNAadducts in
target and surrogate tissues and the exact nature of the
adducts is important information when relating levels of
these DNAadducts topotential hazard outcomesfromthe
exposure.
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